反応式
CC(CC(O)=O)=O.[CH3:8][C:9]1[N:18]=[C:17]([N:19]2[CH2:25][C:24]3[CH:26]=[C:27](B(O)O)[CH:28]=[CH:29][C:23]=3[O:22][CH2:21][CH2:20]2)[C:16]2[CH2:15][C:14]([CH3:34])([CH3:33])[CH2:13][CH2:12][C:11]=2[N:10]=1.[NH2:35][C:36]1[C:41]([S:42]([NH:45][CH2:46][CH:47]2[CH2:52][CH2:51][N:50]([CH3:53])[CH2:49][CH2:48]2)(=[O:44])=[O:43])=[CH:40][C:39](Br)=[CH:38][N:37]=1>>[NH2:35][C:36]1[C:41]([S:42]([NH:45][CH2:46][CH:47]2[CH2:48][CH2:49][N:50]([CH3:53])[CH2:51][CH2:52]2)(=[O:44])=[O:43])=[CH:40][C:39]([C:27]2[CH:28]=[CH:29][C:23]3[O:22][CH2:21][CH2:20][N:19]([C:17]4[C:16]5[CH2:15][C:14]([CH3:34])([CH3:33])[CH2:13][CH2:12][C:11]=5[N:10]=[C:9]([CH3:8])[N:18]=4)[CH2:25][C:24]=3[CH:26]=2)=[CH:38][N:37]=1参加物
4
反応物 3
生成物 1
実験手順
Prepared as a diacetate salt according to the method of example 5 by using [4-(2,6,6-trimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-yl]boronic acid (reagent preparation 23) and 2-amino-5-bromo-N-((1-methylpiperidin-4-yl)methyl)pyridine-3-sulfonamide (reagent preparation 25) in step 1. 1H NMR (400 MHz, DMSO-d6) δ 8.51 (d, 1H), 8.05 (d, 1H), 7.60 (d, 1H), 7.45 (dd, 1H), 7.03 (d, 1H), 6.67 (br s, 2H), 4.57 (s, 2H), 4.30-4.24 (m, 2H), 3.86-3.79 (m, 2H), 2.70-2.61 (m, 6H), 2.40 (s, 2H), 2.33 (s, 3H), 2.08 (s, 3H), 1.87 (s, 6H), 1.69 (t, 2H), 1.62-1.50 (m, 4H), 1.32-1.19 (m, 1H), 1.08-0.95 (m, 2H), 0.84 (s, 6H); MS (EI) for C32H43N7O3S: 606 (MH+).
出典と根拠
- ORDレコード
- ord-6cc3507baeb34e66b50fc3c60ebe91a4
- 出典データセット
- uspto-grants-2014_02
- 特許番号
- US08648066B2
関連ノート
読み込み中…